FSGS

Apr 20, 2026

For decades, patients with focal segmental glomerulosclerosis had no approved treatment. Then Travere Therapeutics did the unthinkable: it turned a Phase 3 setback into a historic approval. Imagine being diagnosed with a progressive kidney disease, one that scars your kidneys from the inside, strips proteins fro...

Sep 16, 2022

Currently, there are no FDA-approved therapies for FSGS. However, the therapeutic focal segmental glomerulosclerosis market in the seven major geographies mainly comprises off-label focal segmental glomerulosclerosis treatment options. The off-label therapies majorly include nonimmune therapies in conjunction wi...